The new crown epidemic in the United States is serious and lasting, and the hope of saving the dilemma is all placed on the vaccine. Therefore, with the vaccine-related biotech industry, stocks soared, and senior executives and board members made huge profits by cashing out by holding shares. As long as vaccine research and development progresses, including government assistance, stocks can be pursued by investors.
U.S. biotechnology pharmaceutical company Moderna has failed to develop new products in its 10-year history of the company, but announced the development of a vaccine at the end of January; it has frequently released news announcements to make progress, and its stock price has tripled, bringing the company's market value to nearly 30 billion. Moderna insiders sold 248 million shares after the company was confirmed to receive federal sponsorship in April.
Coincidentally, on June 26, Vaxart, a company in San Francisco, unexpectedly announced that the COVID-19 vaccine being developed was included in the "Operation Warp Speed" by the US government. Since then, the stock price has soared. The senior executives who received dividend allocations worth millions of yuan a few weeks ago saw that the stock price rose by six times, immediately took profits and made $200 million.
This seems to be a common phenomenon among American biotech companies. The research and development of the new crown pneumonia vaccine has caused its stock price to soar, and the company has high-level holdings within its company, and it has even followed the trend of operating the wave to double its assets.
According to statistics from the New York Times, since March, at least 11 companies, most of which rely on single drugs for success or failure, have sold stocks worth more than 1 billion yuan.
However, some companies are suspected of using claims and participation in rapid action as marketing methods, which has attracted the attention of the government. Vax's vaccine candidate was used in the early experiments of primate , which was part of the rapid action, but in fact, Vax is not one of the key companies that have received government funding and mass production of vaccines.
Some officials of the Ministry of Health and Welfare also suspect that companies such as Wax are trying to exaggerate their position in the rapid action to speculate on stock prices. Anonymous official from the Ministry of Health and Welfare revealed that his doubts have been conveyed to Securities and Exchange Commission .
At the end of June, Armistice Capital, the largest shareholder of Wax, sold almost all of its shares. Generally speaking, companies give dividends to senior management, but they have to wait several months or even years to implement equity ; but due to the company's internal special terms, the holdings can be delivered immediately; CEO Andrei Floroiu also said that this is to raise funds for the development of vaccines.
Niu Niu feels that when the company's stocks rise, executives will cash out and cut leeks. This makes people suspect that your executives don’t believe in the company’s high growth potential. Are these companies still worth investing in?
